NO20021244L - Subenhet-optimaliserte fusjonsproteiner - Google Patents

Subenhet-optimaliserte fusjonsproteiner

Info

Publication number
NO20021244L
NO20021244L NO20021244A NO20021244A NO20021244L NO 20021244 L NO20021244 L NO 20021244L NO 20021244 A NO20021244 A NO 20021244A NO 20021244 A NO20021244 A NO 20021244A NO 20021244 L NO20021244 L NO 20021244L
Authority
NO
Norway
Prior art keywords
subunit
fusion proteins
optimized fusion
optimized
proteins
Prior art date
Application number
NO20021244A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021244D0 (no
Inventor
Dan Pollock
Harry M Meade
Klaus Bosslet
Original Assignee
Genzyme Transgenics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Transgenics Corp filed Critical Genzyme Transgenics Corp
Publication of NO20021244D0 publication Critical patent/NO20021244D0/no
Publication of NO20021244L publication Critical patent/NO20021244L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20021244A 1999-09-17 2002-03-13 Subenhet-optimaliserte fusjonsproteiner NO20021244L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39907999A 1999-09-17 1999-09-17
PCT/US2000/025558 WO2001019842A1 (en) 1999-09-17 2000-09-18 Subunit optimized fusion proteins

Publications (2)

Publication Number Publication Date
NO20021244D0 NO20021244D0 (no) 2002-03-13
NO20021244L true NO20021244L (no) 2002-05-13

Family

ID=23578058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021244A NO20021244L (no) 1999-09-17 2002-03-13 Subenhet-optimaliserte fusjonsproteiner

Country Status (14)

Country Link
EP (1) EP1237900A4 (zh)
JP (1) JP2003509038A (zh)
KR (1) KR20020039346A (zh)
CN (1) CN1379782A (zh)
AU (1) AU781462B2 (zh)
BR (1) BR0014524A (zh)
CA (1) CA2384766A1 (zh)
HU (1) HUP0202702A2 (zh)
IL (1) IL148549A0 (zh)
MX (1) MXPA02002768A (zh)
NO (1) NO20021244L (zh)
NZ (1) NZ517774A (zh)
RU (1) RU2002110116A (zh)
WO (1) WO2001019842A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
JP6505689B2 (ja) * 2013-11-19 2019-04-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化ｂ細胞活性化因子遺伝子を有する非ヒト動物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111748A0 (en) * 1993-12-03 1995-01-24 Zeneca Ltd Proteins
GB9406974D0 (en) * 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US5959171A (en) * 1994-08-17 1999-09-28 Pharming B.V. Method for the production of biologically active polypeptides in a mammal's
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
EP0973934A4 (en) * 1997-02-25 2003-02-05 Genzyme Transgenics Corp NON-SECRETED PROTEINS PRODUCED TRANSGENICALLY
GB9708918D0 (en) * 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
WO1999066054A2 (en) * 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Erythropoietin analog-human serum albumin fusion protein

Also Published As

Publication number Publication date
IL148549A0 (en) 2002-09-12
NO20021244D0 (no) 2002-03-13
WO2001019842A9 (en) 2002-11-14
CA2384766A1 (en) 2001-03-22
AU781462B2 (en) 2005-05-26
RU2002110116A (ru) 2004-03-10
KR20020039346A (ko) 2002-05-25
EP1237900A1 (en) 2002-09-11
BR0014524A (pt) 2002-06-11
AU3883101A (en) 2001-04-17
EP1237900A4 (en) 2005-08-03
HUP0202702A2 (hu) 2002-12-28
MXPA02002768A (es) 2002-08-30
JP2003509038A (ja) 2003-03-11
WO2001019842A1 (en) 2001-03-22
CN1379782A (zh) 2002-11-13
NZ517774A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
NO2022060I1 (no) Aflibercept
DK2236152T3 (da) Albuminfusionsproteiner
FR2800817B1 (fr) Joint homocinetique tripode
IT1313881B1 (it) Giunto omocinetico
NO20016116D0 (no) Substituerte heterocykliske fuserte gamma-karboliner
DE69832542D1 (de) Fusionsimplantat
IS6040A (is) Valdekoxib efnablöndur
NO982097L (no) Peptider
DE60038253D1 (de) Verbindungsmaterial
DE60004380D1 (de) Gelenkanordnung
ID29577A (id) Protein pestisida
GB9913437D0 (en) Fusion proteins
NO20021275D0 (no) Transgent produserte fusjonsproteiner
FR2791348B1 (fr) POLYPEPTIDE Npt2B
NO20004167L (no) Kaspase-8 interagerende proteiner
ATE295417T1 (de) Angiostatin-bindendes protein
NO20021244L (no) Subenhet-optimaliserte fusjonsproteiner
DK0862197T3 (da) Sikringsstik
DE10082298D2 (de) Chimäre Proteine
FI991256A (fi) Apulaite tarjoilua varten
NO20013933D0 (no) Peptider
NO20012283D0 (no) Koblede peptider
DE10084565T1 (de) Verbindungsorgan
NO20013699D0 (no) Meg-4-protein
DE50009295D1 (de) Vernetzerfreie zubereitungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application